Chairman of the Board
Calibr & The Scripps Research Institute
In addition to serving as the Chair of the Scientific Advisory Board for Calibr, Dr. Walsh is a member of the Calibr Board of Directors. Dr. Walsh was the Hamilton Kuhn professor of biological chemistry and pharmacology at Harvard Medical School for 26 years and is now a consulting professor to the Dept of Chemistry at Stanford and a member of Stanford’s ChEM-H Instiute. His research focused on enzymes and enzyme inhibition, and most recently on the problem of antibiotic resistance. Dr. Walsh was elected to the National Academy of Sciences and the Institute of Medicine in 1989. Walsh earned his A.B. degree in biology from Harvard University in 1965 and his Ph.D. in life science in 1970 from Rockefeller University. Walsh completed a postdoctoral fellowship at Brandeis University in 1972, and later that year joined the faculty at Massachusetts Institute of Technology as a professor of chemistry and biology. In 1987, he joined the faculty at Harvard Medical School, where he now has emeritus status. Walsh has authored more than 800 publications in scholarly journals, authored 3 books, and trained 80 graduate students and 150 postdoctoral researchers. Among his professional activities, Walsh is a member of the Board of Scientific Governors of The Scripps Research Institute, as well as an advisor and director of biotechnology companies.
Bioscience Advisors, Inc.
Mark Edwards has over two decades of experience in negotiating and analyzing biopharma alliances. As founder and managing director of Recombinant Capital (Recap) from 1988 until its sale to Deloitte in 2008, Mr. Edwards supervised the creation and maintenance of several databases relating to the development and commercialization of pharmaceutical products, including the Recap Corporate Alliances Database. Over this period, Mr. Edwards and Recap was retained by more than 50 companies to assist in the negotiation of biopharma alliances. His consulting clients have included Abbott, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Millennium, Merck, Pfizer, PTC Therapeutics, Roche and Tularik. In 2008, Mr. Edwards was awarded a Lifetime Achievement Award by the American Liver Foundation for "two decades of leadership, thoughtful insights and detailed analysis of the biotechnology industry." From 2008 through 2010, Mr. Edwards was the managing director of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte LLP. In January 2011, Mr. Edwards founded Bioscience Advisors, Inc. (Biosci), a consulting and database firm focused on biopharma alliances. Biosci has created a database, BiosciDB, that contains copies of over 12,000 license, development, co-development, joint venture, distribution, asset purchase and other arm's-length agreements that have been publicly filed with the U.S. Securities and Exchange Commission (SEC). Mr. Edwards is a charter Certified Licensing Professional as established by the Licensing Executive Society. He is on the board of directors of AcelRx and Calibr and has previously served on the boards of Allos Therapeutics, CombiMatrix and Ontogen. He holds a Bachelor of Arts degree in Political Science and Economics and an MBA, both from Stanford University.
Isy Goldwasser has served on Calibr’s Board of Directors since its inception and brings two decades of experience in managing corporate operations and business development. Mr. Goldwasser is currently the CEO of Thync, Inc. Prior to founding Thync, Mr. Goldwasser joined Symyx Technologies in 1994 and became their first employee in 1995 and served as the CEO. In addition to his 16 years at Symyx, Isy was Khosla Venture’s Entrepreneur-in-Residence in 2010. He is a named inventor on more than 30 US, European and Canadian patents. Mr. Goldwasser received a B.S. degree in Chemical Engineering from the Massachusetts Institute of Technology in 1992 and an M.S. degree in Chemical Engineering from Stanford University in 1994.
Professor Emeritus, University of California, San Francisco
Dr. Herbert W. Boyer is internationally recognized for his pioneering discovery of recombinant DNA which has led to numerous life-saving medicines. Dr. Boyer co-founded Genentech in 1976 with the late venture capitalist Robert Swanson, breaking new ground for both life science technology and new business models. Dr. Boyer was a long time Member of the Board at Genentech (1976-2009), a Member of the Board of Allergan (1994- 2013), and a Trustee of The Scripps Research Institute (1999-2006). Dr. Boyer is an elected member of the National Academy of Science, as well as a fellow in the American Academy of Arts and Sciences. Dr. Boyer earned his bachelor of science degree in biology and chemistry in 1958 from Saint Vincent College and his Ph.D. from the University of Pittsburgh. He has received numerous prestigious awards for his work including the National Medal of Technology and Innovation in 1989 and the National Medal of Science in 1990, both presented at the White House by President George Bush, the Lemelson-MIT Prize in 1996 and the Albany Medical Prize in 2004. Dr. Boyer was also elected to the National Inventors Hall of Fame in 2001. In 2004, Business Week magazine named him one of the "Greatest Innovators of the Past 75 Years" and Parade Magazine named him one of the "Ten Most Important Innovators Who Transformed the World." He was featured on the cover of TIME magazine in 1981 with a story entitled, "Shaping Life in the Lab: The Boom in Genetic Engineering, Genentech's Herb Boyer." Dr. Boyer is now retired and is Professor Emeritus of Biochemistry and Biophysics at the University of California at San Francisco.
The Scripps Research Institute
Richard A. King joined The Scripps Research Institute as Chief Operating Officer in 2016. Mr. King has held senior leadership roles in a variety of life sciences companies. Most recently, from 2010 to 2015, he was chief executive officer and president of AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company developing new pain medications. Prior to AcelRx, King held the position of president and general manager of Tercica, Inc., a biotechnology company (later sold to the Ipsen Group) developing and commercializing new therapeutics to treat short stature, acromegaly and associated metabolic disorders. Prior to Tercica, King was executive vice president of commercial operations at Kos Pharmaceuticals, Inc., a firm developing and commercializing prescription products to treat chronic cardiovascular, metabolic and respiratory diseases. Mr. King holds a B.Sc. in Chemical Engineering from University of Surrey and an M.B.A. from Manchester Business School.